A Signature Inferred from Drosophila Mitotic Genes Predicts Survival of Breast Cancer Patients

Introduction The classification of breast cancer patients into risk groups provides a powerful tool for the identification of patients who will benefit from aggressive systemic therapy. The analysis of microarray data has generated several gene expression signatures that improve diagnosis and allow risk assessment. There is also evidence that cell proliferation-related genes have a high predictive power within these signatures. Methods We thus constructed a gene expression signature (the DM signature) using the human orthologues of 108 Drosophila melanogaster genes required for either the maintenance of chromosome integrity (36 genes) or mitotic division (72 genes). Results The DM signature has minimal overlap with the extant signatures and is highly predictive of survival in 5 large breast cancer datasets. In addition, we show that the DM signature outperforms many widely used breast cancer signatures in predictive power, and performs comparably to other proliferation-based signatures. For most genes of the DM signature, an increased expression is negatively correlated with patient survival. The genes that provide the highest contribution to the predictive power of the DM signature are those involved in cytokinesis. Conclusion This finding highlights cytokinesis as an important marker in breast cancer prognosis and as a possible target for antimitotic therapies.

[1]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[2]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[3]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[4]  Z. Szallasi,et al.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.

[5]  田村 賢司.  Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles , 2007 .

[6]  A. Harris,et al.  Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. , 2007, Cancer letters.

[7]  Y. Okamoto,et al.  Identification of molecular targets in head and neck squamous cell carcinomas based on genome-wide gene expression profiling. , 2007, Oncology reports.

[8]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[9]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[10]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[11]  Trevor Hastie,et al.  Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers , 2006, PLoS medicine.

[12]  Crispin J. Miller,et al.  Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis , 2005, Bioinform..

[13]  S. Jackson,et al.  Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks , 2009, Nature.

[14]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[15]  L. Holmberg,et al.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.

[16]  Robert Tibshirani,et al.  Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma , 2005, PLoS medicine.

[17]  Crispin J. Miller,et al.  Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. , 2007, Cancer research.

[18]  Yusuke Nakamura,et al.  Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells , 2007, Cancer science.

[19]  P Lambin,et al.  Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types , 2008, British Journal of Cancer.

[20]  Matthias Evert,et al.  Oncogenic and tumor suppressive roles of polo‐like kinases in human hepatocellular carcinoma , 2010, Hepatology.

[21]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[22]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[23]  J. Baak,et al.  Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Ash A. Alizadeh,et al.  Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.

[25]  Y. Jeng,et al.  ASPM Is a Novel Marker for Vascular Invasion, Early Recurrence, and Poor Prognosis of Hepatocellular Carcinoma , 2008, Clinical Cancer Research.

[26]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[27]  Gregory D. Schuler,et al.  Database resources of the National Center for Biotechnology Information: update , 2004, Nucleic acids research.

[28]  Timothy J Mitchison,et al.  Animal cytokinesis: from parts list to mechanisms. , 2006, Annual review of biochemistry.

[29]  D. Coppola,et al.  Substantially reduced expression of PIAS1 is associated with colon cancer development , 2009, Journal of Cancer Research and Clinical Oncology.

[30]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Horvath,et al.  Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target , 2006, Proceedings of the National Academy of Sciences.

[32]  Gavin D. Grant,et al.  Common markers of proliferation , 2006, Nature Reviews Cancer.

[33]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[34]  J. Peterse,et al.  Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. , 1992, Human pathology.

[35]  Giovanni Cenci,et al.  Identification of Drosophila Mitotic Genes by Combining Co-Expression Analysis and RNA Interference , 2008, PLoS genetics.

[36]  A. Fields,et al.  The guanine nucleotide exchange factor (GEF) Ect2 is an oncogene in human cancer. , 2010, Advances in enzyme regulation.

[37]  Axel Hausen,et al.  Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers , 2009, Breast Cancer Research and Treatment.

[38]  W. Zhong,et al.  Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. , 2009, The Journal of investigative dermatology.

[39]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[40]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Dupuy,et al.  Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. , 2007, Journal of the National Cancer Institute.

[42]  Yusuke Nakamura,et al.  ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. , 2005, Cancer research.

[43]  J. Baak,et al.  Prognostic value of proliferation in invasive breast cancer: a review , 2004, Journal of Clinical Pathology.

[44]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[45]  Marcin Skrzypski,et al.  Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung , 2008, Clinical Cancer Research.

[46]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[47]  Carlos Caldas,et al.  A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer , 2008, Breast Cancer Research.

[48]  Jan P. A. Baak,et al.  Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age , 2009, Breast Cancer Research and Treatment.